Your browser doesn't support javascript.
Altered subgenomic RNA abundance provides unique insight into SARS-CoV-2 B.1.1.7/Alpha variant infections.
Parker, Matthew D; Stewart, Hazel; Shehata, Ola M; Lindsey, Benjamin B; Shah, Dhruv R; Hsu, Sharon; Keeley, Alexander J; Partridge, David G; Leary, Shay; Cope, Alison; State, Amy; Johnson, Katie; Ali, Nasar; Raghei, Rasha; Heffer, Joe; Smith, Nikki; Zhang, Peijun; Gallis, Marta; Louka, Stavroula F; Hornsby, Hailey R; Alamri, Hatoon; Whiteley, Max; Foulkes, Benjamin H; Christou, Stella; Wolverson, Paige; Pohare, Manoj; Hansford, Samantha E; Green, Luke R; Evans, Cariad; Raza, Mohammad; Wang, Dennis; Firth, Andrew E; Edgar, James R; Gaudieri, Silvana; Mallal, Simon; Collins, Mark O; Peden, Andrew A; de Silva, Thushan I.
  • Parker MD; Sheffield Biomedical Research Centre, The University of Sheffield, Sheffield, UK.
  • Stewart H; Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, UK.
  • Shehata OM; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Lindsey BB; Department of Biomedical Science, The University of Sheffield, Western Bank, Sheffield, UK.
  • Shah DR; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Hsu S; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Keeley AJ; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Partridge DG; Sheffield Bioinformatics Core, The University of Sheffield, Sheffield, UK.
  • Leary S; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Cope A; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • State A; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Johnson K; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Ali N; Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia.
  • Raghei R; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Heffer J; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Smith N; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Zhang P; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Gallis M; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Louka SF; IT Services, The University of Sheffield, Sheffield, UK.
  • Hornsby HR; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Alamri H; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Whiteley M; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Foulkes BH; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Christou S; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Wolverson P; Department of Biomedical Science, The University of Sheffield, Western Bank, Sheffield, UK.
  • Pohare M; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Hansford SE; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Green LR; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Evans C; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Raza M; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Wang D; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Firth AE; The Florey Institute for Host-Pathogen Interactions & Department of Infection, Immunity and Cardiovascular Disease, Medical School, University of Sheffield, Sheffield, UK.
  • Edgar JR; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Gaudieri S; Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
  • Mallal S; Sheffield Biomedical Research Centre, The University of Sheffield, Sheffield, UK.
  • Collins MO; Department of Computer Science, The University of Sheffield, Sheffield, UK.
  • Peden AA; Department of Pathology, University of Cambridge, Cambridge, UK.
  • de Silva TI; Department of Pathology, University of Cambridge, Cambridge, UK.
Commun Biol ; 5(1): 666, 2022 07 05.
Article in English | MEDLINE | ID: covidwho-1921725
ABSTRACT
B.1.1.7 lineage SARS-CoV-2 is more transmissible, leads to greater clinical severity, and results in modest reductions in antibody neutralization. Subgenomic RNA (sgRNA) is produced by discontinuous transcription of the SARS-CoV-2 genome. Applying our tool (periscope) to ARTIC Network Oxford Nanopore Technologies genomic sequencing data from 4400 SARS-CoV-2 positive clinical samples, we show that normalised sgRNA is significantly increased in B.1.1.7 (alpha) infections (n = 879). This increase is seen over the previous dominant lineage in the UK, B.1.177 (n = 943), which is independent of genomic reads, E cycle threshold and days since symptom onset at sampling. A noncanonical sgRNA which could represent ORF9b is found in 98.4% of B.1.1.7 SARS-CoV-2 infections compared with only 13.8% of other lineages, with a 16-fold increase in median sgRNA abundance. We demonstrate that ORF9b protein levels are increased 6-fold in B.1.1.7 compared to a B lineage virus in vitro. We hypothesise that increased ORF9b in B.1.1.7 is a direct consequence of a triple nucleotide mutation in nucleocapsid (28280GAT > CAT, D3L) creating a transcription regulatory-like sequence complementary to a region 3' of the genomic leader. These findings provide a unique insight into the biology of B.1.1.7 and support monitoring of sgRNA profiles to evaluate emerging potential variants of concern.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03565-9

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA / COVID-19 Type of study: Diagnostic study / Experimental Studies / Prognostic study Topics: Variants Limits: Humans Language: English Journal: Commun Biol Year: 2022 Document Type: Article Affiliation country: S42003-022-03565-9